|
Market Closed -
Nasdaq
16:00:00 2026-10-21 EDT
|
5-day change | 1st Jan Change | ||
| 138.08 USD | +0.07% |
|
-0.30% | +58.09% |
Company Valuation: Protagonist Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,632 | 536.8 | 1,323 | 2,300 | 5,460 | 8,929 | - | - |
| Change | - | -67.12% | 146.4% | 73.94% | 137.35% | 63.53% | - | - |
| Enterprise Value (EV) 1 | 1,305 | 411 | 1,136 | 2,203 | 5,332 | 8,402 | 8,435 | 8,339 |
| Change | - | -68.51% | 176.35% | 93.98% | 142% | 57.59% | 0.39% | -1.14% |
| P/E | -12.6x | -4.2x | -16.5x | 9.13x | -42.6x | 29.7x | -456x | 76.6x |
| PBR | - | - | - | - | - | 9.22x | 9.58x | 8.07x |
| PEG | - | 1.03x | 0.4x | -0x | 0x | -0x | 4x | -0x |
| Capitalization / Revenue | 59.7x | 20.2x | 22x | 5.3x | 119x | 16.3x | 41.4x | 24x |
| EV / Revenue | 47.7x | 15.5x | 18.9x | 5.07x | 116x | 15.3x | 39.1x | 22.4x |
| EV / EBITDA | -10.4x | - | -12.3x | 8.69x | -34x | 28.5x | -102x | 68.7x |
| EV / EBIT | -10.4x | -3.13x | -12.1x | 8.71x | -33.7x | 27x | -148x | 76.9x |
| EV / FCF | -12x | -3.77x | -16x | 12.1x | 95.1x | 26.1x | 47.7x | 30.4x |
| FCF Yield | -8.35% | -26.5% | -6.24% | 8.3% | 1.05% | 3.84% | 2.1% | 3.29% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.71 | -2.6 | -1.39 | 4.23 | -2.05 | 4.648 | -0.303 | 1.803 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 27.36 | 26.58 | 60 | 434.4 | 46.02 | 549 | 215.5 | 372 |
| EBITDA 1 | -125 | - | -92.68 | 253.7 | -156.8 | 294.7 | -82.9 | 121.3 |
| EBIT 1 | -125.8 | -131.4 | -93.65 | 252.8 | -158.1 | 311.1 | -56.91 | 108.4 |
| Net income 1 | -125.6 | -127.4 | -78.96 | 275.2 | -130.1 | 326.2 | -18.36 | 137.1 |
| Net Debt 1 | -326.9 | -125.7 | -186.7 | -97.25 | -128.4 | -526.9 | -494.2 | -590 |
| Reference price 2 | 34.20 | 10.91 | 22.93 | 38.60 | 87.34 | 138.08 | 138.08 | 138.08 |
| Nbr of stocks (in thousands) | 47,728 | 49,198 | 57,678 | 59,598 | 62,516 | 64,708 | - | - |
| Announcement Date | 2/28/22 | 3/15/23 | 2/27/24 | 2/21/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 30.65x | 15.51x | 28.51x | -.--% | 8.93B | |
| 19.21x | 6.83x | 13.69x | 1.55% | 66.34B | |
| 36.32x | 6.47x | 19.31x | 0.89% | 52.92B | |
| 29.51x | 8.11x | 25.65x | 0.05% | 54.82B | |
| 34.13x | 3.33x | 14.37x | -.--% | 44.09B | |
| 50.62x | 5.85x | 32.15x | -.--% | 43.72B | |
| -20.41x | 209.35x | -21.69x | -.--% | 42.13B | |
| 29.48x | 8.35x | 21.6x | 0.36% | 33.96B | |
| 30.25x | 6.41x | 16.63x | -.--% | 26.17B | |
| 31.94x | 5.89x | 19.81x | -.--% | 23.37B | |
| Average | 27.17x | 27.61x | 17.00x | 0.28% | 39.64B | |
| Weighted average by Cap. | 26.45x | 28.23x | 16.01x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- PTGX Stock
- Valuation Protagonist Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
